Patents by Inventor Ian J Constable
Ian J Constable has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220111015Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: May 24, 2021Publication date: April 14, 2022Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG, Jr.
-
Publication number: 20180311319Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: April 24, 2018Publication date: November 1, 2018Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG
-
Patent number: 10004788Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: GrantFiled: December 21, 2017Date of Patent: June 26, 2018Assignee: Avalanche Australia Pty Ltd.Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
-
Publication number: 20180125948Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: December 21, 2017Publication date: May 10, 2018Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG, Jr.
-
Patent number: 9943573Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: GrantFiled: May 19, 2014Date of Patent: April 17, 2018Assignee: Avalanche Australia PTY Ltd.Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
-
Publication number: 20150004101Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: May 19, 2014Publication date: January 1, 2015Applicant: Avalanche Australia Pty Ltd.Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
-
Publication number: 20140371438Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: May 19, 2014Publication date: December 18, 2014Applicant: Avalanche Australia Pty Ltd.Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
-
Publication number: 20140341977Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: Avalanche Australia Pty Ltd.Inventors: Ian J. Constable, Elizabeth P. Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
-
Publication number: 20130323302Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.Type: ApplicationFiled: May 7, 2013Publication date: December 5, 2013Applicants: Lions Eye Institute Limited, Avalanche Australia Pty Ltd.Inventors: Ian J. Constable, Elizabeth P. Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
-
Publication number: 20030055497Abstract: Disclosed are improved methods of insertion of keratoprosthesis and, in particular, improved methods of surgical insertion and placement of a soft hydrogel prosthetic corneal device into the host cornea. The methods of the invention provide greatly improved rates of success for the implantation and retention of the device.Type: ApplicationFiled: July 23, 2002Publication date: March 20, 2003Applicant: The Lions Instutute of Western Australia IncorporatedInventors: Celia R. Hicks, Geoffrey J. Crawford, Traian V. Chirila, Ian J. Constable
-
Patent number: 6423093Abstract: Disclosed is a method of insertion of keratoprostheses, and in particular, a method of surgical insertion and placement of a soft hydrogel prosthetic corneal device into the host cornea. The method of the invention provides a greatly improved rate of success for the implantation and retention of the device.Type: GrantFiled: July 26, 2000Date of Patent: July 23, 2002Assignee: The Lions Eye Institute of Western Australia IncorporatedInventors: Celia R Hicks, Geoffrey J Crawford, Traian V Chirila, Ian J Constable
-
Patent number: 5458819Abstract: A composite device which may be implanted in the cornea of the human eye to replace damaged or diseased portions, and a method of manufacturing the said device, are disclosed. The device consists of a transparent central portion intimately attached to an opaque spongy rim. Both portions are made of hydrogel materials produced in different conditions of polymerization during a two-stage process performed in a specific moulding unit. The spongy rim promotes and maintains cellular invasion from the host corneal tissue, thus providing a tight union between implant and recipient cornea which prevents the postoperative extrusion of the implant.Type: GrantFiled: December 20, 1993Date of Patent: October 17, 1995Assignee: Lions Eye Institute of Western Australia, IncorporatedInventors: Traian V. Chirila, Ian J. Constable, Geoffrey J. Crawford, Albert V. Russo
-
Patent number: 5300116Abstract: A composite device which may be implanted in the cornea of the human eye to replace damaged or diseased portions, and a method of manufacturing the said device, are disclosed. The device consists of a transparent central portion intimately attached to an opaque spongy rim. Both portions are made of hydrogel materials produced in different conditions of polymerization during a two-stage process performed in a specific moulding unit. The spongy rim promotes and maintains cellular invasion from the host corneal tissue, thus providing a tight union between implant and recipient cornea which prevents the postoperative extrusion of the implant.Type: GrantFiled: August 14, 1992Date of Patent: April 5, 1994Assignee: Lions Eye Institute of Western AustraliaInventors: Traian V. Chirila, Ian J. Constable, Geoffrey J. Crawford, Albert V. Russo
-
Patent number: 5252628Abstract: A method of making pigmented hydrophilic polymers in such a manner that the resulting polymers absorb ultraviolet and visible radiation, and that no migration, separation or leaching of the pigment can take place, is disclosed. The polymer compositions comprise blends of hydrophilic polymers with melanin pigments, the latter being synthesized on the hydrophilic polymer matrix. The disclosed polymer compositions are useful in the manufacture of ocular devices, particularly intraocular lenses and aphakic contact lenses capable of absorbing ultraviolet and visible radiation, at wavelengths between 300 and 700 nanometers, to the same extent as the natural crystalline lens of the eye. The disclosed method is also useful to impart photoprotective properties to the already made said ocular devices.Type: GrantFiled: December 7, 1989Date of Patent: October 12, 1993Assignee: Lions Eye Institute of Western Australia, Inc.Inventors: Traian V. Chirila, Ian J. Constable, Richard L. Cooper